Publication: Expression and roles of system L amino acid transporters in human embryonal carcinoma cells
Issued Date
2020-01-01
Resource Type
ISSN
20472927
20472919
20472919
Other identifier(s)
2-s2.0-85089580728
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Andrology. (2020)
Suggested Citation
Kasit Chatsirisupachai, Sarunya Kitdumrongthum, Wittaya Panvongsa, Keatdamrong Janpipatkul, Wittawin Worakitchanon, Sarat Lertjintanakit, Patompon Wongtrakoongate, Arthit Chairoungdua Expression and roles of system L amino acid transporters in human embryonal carcinoma cells. Andrology. (2020). doi:10.1111/andr.12880 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/58990
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Expression and roles of system L amino acid transporters in human embryonal carcinoma cells
Other Contributor(s)
Abstract
© 2020 American Society of Andrology and European Academy of Andrology Background: Testicular germ cell tumors (TGCTs) are the most common malignant cancer in young men. Although TGCTs are generally responsive to platinum-based chemotherapy particularly cisplatin, acquired resistance in patients with metastasis still occurs resulting in poor prognosis. Specifically, differentiation of embryonal carcinoma (EC) cells, the stem cells of TGCTs, can lead to the reduction of cisplatin responsiveness. Therefore, novel therapeutic strategies for TGCTs are needed. System L amino acid transporters have been reported to be up-regulated and to play an important role in tumorigenesis. However, expression and role of system L amino acid transporters in TGCTs remain elusive. Materials and methods: Expression of system L amino acid transporters was analyzed in TGCT samples from The Cancer Genome Atlas (TCGA). Expression of LAT1, LAT2, and 4F2hc was examined in human embryonal carcinoma cell line NTERA2. Roles of system L amino acid transporters on NTERA2 cell survival, cell proliferation, pluripotency, and cisplatin sensitivity were evaluated. Results: Based upon TCGA datasets, we found that two isoforms of system L (LAT1 and LAT2) and their chaperone protein 4F2hc are highly expressed in EC samples compared with other groups. Treatment with the system L inhibitor BCH significantly suppressed leucine uptake into the pluripotent EC cell line NTERA2. The malignant phenotypes including cell viability, cell proliferation, and clonal ability were decreased following BCH treatment. Nonetheless, system L inhibition did not alter expression of stemness genes in NTERA2 cells. After NTERA2 differentiation, expressions of LAT1 and LAT2 were decreased. Finally, co-administration of BCH enhanced cisplatin sensitivity in both undifferentiated and differentiated cells. These effects were associated with the reduction in p70S6K phosphorylation. Conclusion: Taken together, these results shed light on the roles of system L amino acid transporters in TGCTs. Therefore, system L amino acid transporters could provide novel therapeutic targets for treatment against TGCTs.